The Conversation (0)
PBR reports that US-based novel drug developer Isis Pharmaceuticals (NASDAQ:ISIS) has received a payment of $6m from AstraZeneca (LSE:AZN) to continue their contract research agreement to discover and develop new antisense therapeutics to treat cancer.
PBR reports that US-based novel drug developer Isis Pharmaceuticals (NASDAQ:ISIS) has received a payment of $6m from AstraZeneca (LSE:AZN) to continue their contract research agreement to discover and develop new antisense therapeutics to treat cancer.
As quoted in the market news:
Commenting on the research partnership, Isis Pharmaceuticals chief operating officer Lynne Parshall said, “Our oncology franchise consists of five antisense drugs in development to treat patients with a variety of cancers.”